CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.
about
Two gene polymorphisms (rs4977756 and rs11515) in CDKN2A/B and glioma risk in South Indian population.Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor.Correlation between indoleamine 2,3 dioxygenase mRNA and CDKN2A/p16 mRNA: a combined strategy to cervical cancer diagnosis.
P2860
CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
CDKN2A (p16) mRNA decreased ex ...... n malignant high-grade glioma.
@en
CDKN2A
@nl
type
label
CDKN2A (p16) mRNA decreased ex ...... n malignant high-grade glioma.
@en
CDKN2A
@nl
prefLabel
CDKN2A (p16) mRNA decreased ex ...... n malignant high-grade glioma.
@en
CDKN2A
@nl
P2093
P2860
P1433
P1476
CDKN2A (p16) mRNA decreased ex ...... n malignant high-grade glioma.
@en
P2093
Ch Lavanya
Dhananjaya I Bhat
G K Chetan
K V L Narasingarao
P2860
P2888
P304
P356
10.1007/S13277-015-3480-5
P577
2015-04-29T00:00:00Z